In SCCS, median PSA was 0.9, 75th percentile was 1.4 and 90th was 2.8. We created both unweighted and weighted genetic risk scores (GRS) based on SNPs identified to be associated with PSA in the Hoffman et al. Nat Genet. 2017 GWAS of PSA levels. GRS was used to adjust PSA values and then we assessed logistic regression models and AUC results.
INTRODUCTION AND OBJECTIVES:
A 2-gene, urine-based molecular test that combines mRNA biomarkers with clinical factors can risk stratify patients for high-grade prostate cancer (PCa). To ensure the generalizability of the risk score, the model was optimized and validated for patients from three European countries who were undergoing initial prostate biopsy.
METHODS: The study population consisted of 1956 men suspected of PCa from The Netherlands, France and Germany who underwent initial prostate biopsies between December 2007 and December 2014. The median age was 65 years (interquartile range 60-70), median serum PSA 6.3 ng/mL 3) and 485/1956 (25%) had abnormal DRE results. PCa was detected in 991/1956 (51%) men biopsied: 46% ISUP grade group (GG) 1, 27% GG2, 12% GG3, 7% GG4 and 8% GG5. The prevalence of GG2-5 PCa was 27.6% (540/1956 ).
Post-DRE urine was collected from all subjects prior to biopsy, and samples were stored at -700C. Urinary HOXC6 and DLX-1 mRNAs were quantified by PCR (MDxHealth, Irvine CA), and the RNA results were next combined with other risk factors (age, serum PSA level, DRE, prostate volume and family history of PCa) to determine the likelihood that subsequent biopsy would identify GG > 2 (Gleason Score > 7) PCa.
SUBJECTS were divided into Discovery (N[1040) and Validation (N[916) cohorts: the Dutch cohorts have been previously described*, French and German groups were evenly split by randomization. The combination of multiple risk factors was assessed by generating linear models, resulting in a continuous Risk Score. Models were optimized for maximum sensitivity and negative predictive value (NPV) for GG2 PCa in subjects with PSA <10 ng/mL. Clinical performance was assessed at a fixed Risk Score cutoff of -2.8*. The PCPT RESULTS: For the Discovery set, the optimal model included urinary HOXC6þDLX1, age, DRE and PSA density (serum PSA/prostate volume). For the Validation set, the AUC was 0.87, sensitivity 95%, specificity 49% and NPV 96%, whereas the PCPTRC AUC was 0.69 (0.65-0.74), with sensitivity of 95% and specificity of 16%. For the subset of patients with PSA < 10 ng/mL, the Validation set yielded an AUC of 0.82 (0.79-0.86), sensitivity 89%, specificity 53% and NPV 95%. Overall performance for the combined Discovery and Validation cohorts (all PSA levels, N[1956) was AUC 0.85 (0.83-0.87), with sensitivity and NPV of 95% and 96%, respectively.
CONCLUSIONS: The biomarker-based clinical model, optimized primarily for biopsy naive patients with serum PSA < 10 ng/mL, demonstrated high sensitivity and NPV for detection of GG2 and higher PCa across all patient groups. Clinical performance characteristics were equivalent to the published clinical validation study. These data support use of the test to help guide initial prostate biopsy decisions.
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Sandra Gaston*, Boston, MA; Rick Kittles, Duarte, CA; Soroush Rais-Bahrami, Peter Kolettis, James Bryant, Jeffrey Nix, Birmingham, AL; Mark DeGuenther, George Adams, Homewood, AL; Ebony Shah, Indianapolis, IN; James Kearns, Ravi Chinsky, Kerry Dehimer, Norma Terrin, Hong Chang, Boston, MA; William Grizzle, Birmingham, AL INTRODUCTION AND OBJECTIVES: Concerns about overtreatment of clinically indolent prostate cancer (PrCa) have led to recommendations for less screening, fewer biopsies, and the management of low-risk PrCa by active surveillance rather than immediate definitive treatment. However the risk of missing or failing to treat an aggressive prostate PrCa can be a significant source of anxiety. The uncertainty is particularly keen for African American (AA) men who are about 1.7 times more likely to be diagnosed with PrCa and about 2.4 times more likely to die of this disease. Many studies show that genetic factors play a role in the increased risk of PrCa in AA. The AA population, as many other populations in the Americas, is genetically heterogeneous with varying degrees of admixture from West Africans, Europeans and Native Americans. Recommendations for PrCa screening and management rarely consider potential differences in risk within the AA population. METHODS: 96 consecutive eligible self-identified AA men were prospectively enrolled in this study. We compared West African (WA) genetic ancestry in the men who were diagnosed with no cancer, low grade PrCa (Gleason Sum 6) or higher grade PrCa (GS 7-10) on a stand-of-care systematic prostate biopsy. Each man's WA, European and Native American ancestry was estimated by DNA testing using a panel of 105 ancestry informative markers (single nucleotide polymorphisms).
RESULTS: We found that WA genetic ancestry was significantly higher in AA men who were diagnosed with PrCa on biopsy, compared to AA men who were cancer negative, and was highest in AA men who were diagnosed with higher grade PrCa (GS 7-10). We evaluated % WA ancestry as a predictor of GS 7-10 cancer both as a single variable and in combination with other variables used clinically to make decisions about whether a patient should undergo prostate biopsy. For prediction of any cancer on biopsy, addition of WA genetic ancestry to a base model that includes age, PSA and prostate volume increases the model R square by 75% with P [ 0.0245. For predicting GS 7-10 cancer, addition of WA ancestry to the base model improves R square by 72% with P [ 0.0238. Thus when considered in combination with age, PSA and prostate size, % WA ancestry remained a strong predictor of both PrCa diagnosis and GS 7-10 cancer on biopsy.
CONCLUSIONS: Incorporating West African ancestry into the guidelines for making decisions about when to obtain a biopsy and whether to choose active surveillance may allow AA men to personalize their approach to prostate cancer screening and management. (Bx) . We sought to investigate a combination of 4Kscore and mpMRI to improve diagnostic performance, and potentially further reduce Bx rates compared to the individual tests alone METHODS: This was a retrospective, five-center study of men who underwent a 4Kscore, mpMRI, and Bx. Results from mpMRI were reported using PIRADS and categorized into low (PIRADS 1-2), intermediate (PIRADS 3) and high (PIRADS 4-5). The 4Kscore is reported as a continuous probability of high-grade GG2 or higher cancer (HG), here categorized into low (<7%), intermediate (8%-32%), and high (>33%) risk. The primary endpoint was to evaluate potential Bx reduction, sensitivity, negative predictive value (NPV), and undetected HG cancers when using Single Test or Combination Test strategies for Bx decision-making. We evaluated using either test alone, versus both tests in sequence. With Single Test, patients were stratified with low risk results avoiding a Bx and intermediate or high risk getting a Bx. With Combination Test, high-risk patients by the first test would receive a Bx and low risk would not. For intermediate risk patients, the second test would be used for determining if a Bx would occur (Fig. 1) .
RESULTS: The final cohort included 407 men, of which 114 were found to have a HG cancer. Using a 4Kscore or MRI alone, resulted in a 25-27% biopsy reduction, with 8-12 men having an undetected HG. Combination strategies yielded higher specificities, leading to larger biopsy reductions in the range of 38-41%, while 11-15 men had an undetected HG. Sensitivity and NPV did not appreciably differ between strategies (Table 1) . Similar results were found in the category of men with a PSA of 2-10 and 3-10 ng/mL. CONCLUSIONS: Combining 4Kscore and mpMRI to make prostate Bx decisions could further reduce Bx rates, while improving specificity for high-grade cancer, with minimal changes to NPV and sensitivity Evidence for an effect of ASA on PCa is conflicting. The exact interaction pathways between ASA and carcinogenesis are still to be established. The aim of the study was to analyze the influence of ASA intake on PSA values and PCa development.
METHODS: A population-based analysis including 4314 men from the European Randomized Study of Screening for Prostate Cancer (ERSPC) database was conducted. Data about drug intake, age, family history and symptoms was obtained by a self-administered questionnaire. A transrectal ultrasound guided prostate biopsy was performed in men with a PSA-level > 3 ng/ml. Tumor stage and grade were registered; incidence and mortality data were obtained through registry linkages. PCa incidence and grade, total PSA value, free-to-total PSA and overall survival were compared between ASA users and non-users, respectively. RESULTS: Median follow-up time was 9.6 years. In all, n [ 789 (18.3%) men used aspirin [ASAþ] . Although overall PCa incidence was significantly lower among aspirin users ([ASAþ] 54 (6.8%) vs. [ASA-] 338 (9.6%), p 0.015), the multivariate cox-regression analysis did not show the decreased risk to be diagnosed with PCa ([ASAþ] hazard ratio (HR) 0.84, 95% confidence interval (CI) 0.62 -1.16; p [ 0.297) to be statistically significant. Total PSA values were significantly lower in aspirin users for both baseline (1.6 vs. 1.8 ng/ml, p [ 0.007) and
